Repeated Nitrogen Dioxide Exposures and Eosinophilic Airway Inflammation in Asthmatics: A Randomized Crossover Study

Véronique Ezratty,1 Gaëlle Guillossou,1 Catherine Neukirch,2 Monique Koscielny,3 Marcel Bonay,5 Pierre-André Cabanes,1 Jonathan M. Samet,6 Patrick Mure,7 Luc Ropert,7 Sandra Tokarek,7 Jacques Lambrozo,1 and Michel Aubier2

1Service des Études Médicales (SEM), EDF, Levallois-Perret, France; 2Service de Pneumologie A, Clinical Center of Investigation, Inserm U700, Bichat Hospital, Université Paris Diderot, DHU FIRE, Paris, France; 3Laboratoire de Biochimie, Bichat Hospital, Paris, France; 4Service de biostatistiques et épidémiologie, Gustave Roussy, Villejuif, France; 5Department of Physiology, Bichat Hospital, Paris, France; 6Department of Preventive Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, Los Angeles, California, USA; 7Center for Research & Innovation in Gas and New Energy Sources, CRIGEN, GDF SUEZ, St-Denis, France

BACKGROUND: Nitrogen dioxide (NO₂), a ubiquitous atmospheric pollutant, may enhance the asthmatic response to allergens through eosinophilic activation in the airways. However, the effect of NO₂ on inflammation without allergen exposure is poorly studied.

OBJECTIVES: We investigated whether repeated peaks of NO₂ at various realistic concentrations, induce changes in airway inflammation in asthmatics.

METHODS: Nineteen nonsmokers with asthma were exposed at rest in a double-blind, crossover study, in randomized order, to 200 ppb NO₂, 600 ppb NO₂, or clean air once for 30 min on day 1 and twice for 30 min on day 2. The three series of exposures were separated by 2 weeks. The inflammatory response in sputum was measured 6 hr (day 1), 32 hr (day 2), and 48 hr (day 3) after the first exposure, and compared with baseline values measured twice 10–30 days before the first exposure.

RESULTS: Compared with baseline measurements, the percentage of eosinophils in sputum increased by 57% after exposure to 600 ppb NO₂ (p = 0.003) but did not change significantly after exposure to 200 ppb. The slope of the association between the percentage of eosinophils and NO₂ exposure level was significant (p = 0.04). Eosinophil cationic protein in sputum was highly correlated with eosinophil count and increased significantly after exposure to 600 ppb NO₂ (p = 0.001). Lung function, which was assessed daily, was not affected by NO₂ exposure.

CONCLUSIONS: We observed that repeated peak exposures of NO₂ performed without allergen exposure were associated with eosinophilic airway inflammation in asthmatics in a dose-related manner.


Introduction

Nitrogen dioxide (NO₂), a ubiquitous atmospheric pollutant, is a respiratory irritant that remains a matter of concern [World Health Organization (WHO) European Centre for Environment and Health and WHO Regional Office for Europe 2013]. Indoor concentrations of NO₂ often exceed those found outdoors, especially when unvented combustion appliances are used. Inside homes, peak levels of NO₂, associated with the use of gas and solid-fuel appliances for cooking and heating, have been measured in the range of 80–1,100 ppb (150–2,090 μg/m³) (Basu and Samet 1999; Dennekamp et al. 2001; Kotzias et al. 2005; Pilotto et al. 1997). Outdoors, hourly NO₂ concentrations in cities rarely exceed 200 ppb (380 μg/m³) (U.S. Environmental Protection Agency 2008), although urban levels can reach levels as high as 500 ppb (950 μg/m³) (WHO 2006), especially for short periods in streets with heavy traffic and in road tunnels (Larsson et al. 2010).

Epidemiological and controlled human exposure studies suggest that people with asthma are more susceptible to the effects of NO₂ when compared with healthy individuals (Bauer et al. 1986; Belanger et al. 2006; Bylin et al. 1988; Hasselblad et al. 1992; Jaros and Magnusson 1990; Strand et al. 1996).

However, despite the extensive literature on NO₂-induced health effects, some inconsistencies in the results of studies have been noted (Jarvis et al. 2010). In asthmatics, NO₂ exposure without allergen challenge did not result in lung functional changes in most studies (Avol et al. 1988; Kleinman et al. 1983; Linn et al. 1986; Mohsenin 1987), and inconsistent results were found in airway responsiveness after nonspecific bronchoconstrictor challenges (Bylin et al. 1988; Hazucha et al. 1983; Jaros and Magnusson 1991; Kleinman et al. 1983; Roger et al. 1990; Strand et al. 1996). After allergen challenge, exposure to NO₂ in asthmatics increased airway hyper-responsiveness (Jenkins et al. 1999; Strand et al. 1997, 1998; Tunnicliffe et al. 1994) and eosinophilic inflammation (Barck et al. 2002, 2005).

A few studies have investigated the inflammatory response to a single exposure of NO₂ without allergen challenge in asthmatics, but the findings have been inconsistent (Jaros et al. 1995; Solomon et al. 2004; Vagaggini et al. 1996).

We investigated whether repeated brief exposures to 200 ppb (380 μg/m³) and 600 ppb (1,130 μg/m³) NO₂, which mimic indoor NO₂ peaks, enhance airway inflammation in asthmatics. This clinical study involved 19 adults with intermittent asthma and used a randomized double-blind protocol with assessment of inflammatory response in induced sputum.

Materials and Methods

Participants: Nineteen patients [14 men and 5 women; median age, 29 years; age range, 20–69 years; median body mass index (BMI), 26 kg/m²; BMI range, 20–39 kg/m²] were included in the study (Table 1). All had intermittent asthma as defined by the Global Initiative for Asthma (2010) guidelines and were nonsmokers (18 had never smoked and 1 had stopped smoking some 10 years earlier).

Address correspondence to V. Ezratty, Service des Études Médicales (SEM), EDF–DRH GROUPE, 45 rue Kleber, Site Carré Vert, 92300 Levallois–Perret, France. Telephone: 00 33 (1) 82 24 84 43. E-mail: veronique.ezratty@edf.fr

Supplemental Material is available online (http://dx.doi.org/10.1289/ehp.1307240).

We thank the following for their contributions: I. Poirier, H. Casterman, S. Billot-Bonef, M. Bonnet-Bellais, E. Pigeon, S. Maestri, B. Vandercauwede, L. Alavoine, L. Nardelli, A. Boulmeau, L. Dejoie, Y. Retory, S. de Ferrières, and D. Ormandy. All statistical analyses were performed by S. Koscielny, Service de bio-statistiques et épidémiologie, Gustave Roussy, Villejuif, France.

This study was supported by the Center for Research & Innovation in Gas and New Energy Sources, CRIGEN, GDF SUEZ; the Medical Studies Department of EDF; and the Clinical Center of Investigation at Bichat Hospital, Paris, France.

The authors’ freedom to design, conduct, interpret and submit for publication the research described in this work was not compromised by any of the funding bodies.

V.E., G.G., P.-A.C., and J.L. are employed by EDF, Service des Études Mé dicales (SEM), Levallois-Perret, France. P.M., L.R., and S.T. are employed by GDF-SUEZ, Center for Research & Innovation in Gas and New Energy Sources CRIGEN, St-Denis, France. The other authors declare they have no actual or potential competing financial interests.

Received: 18 June 2013; Accepted: 15 April 2014; Advance Publication: 18 April 2014; Final Publication: 1 August 2014.
Only patients who had a diagnosis of asthma confirmed by a positive methacholine challenge performed twice at baseline 10–30 days before the first exposure were included in the study. A positive methacholine test was defined as a methacholine provocative dose causing a 20% decrease in forced expiratory volume in 1 sec (FEV1) from control FEV1 (PD20 methacholine) < 4 mg. All participants had allergy to house dust mites (HDM) and/or pollen confirmed by a positive skin-prick test done ≥ 4 weeks before their inclusion in the study. The study was performed outside the pollen season for those who had been diagnosed with pollen allergies. Of the 19 participants, 6 had a personal history of atopic dermatitis and/or an atopic familial history. None of those six used inhaled or oral corticosteroids or other antiinflammatory therapy, and the only permitted medication was an inhaled β2-agonist, used as needed during the study period (from baseline, i.e., 30 days before the first NO2 exposure until the end of the study 2 weeks after the last exposure). Participants who had gas stoves and/or unventilated combustion appliances at home were told not to use them at baseline and on the days of exposures and during the 2 days before and after NO2 exposure. All participants had to be free of airway infection for at least 6 weeks before baseline measurements.

The study was registered by the French Ministry of Health (DGS 2006/0016) and approved by the Ethics Committee of Hotel-Dieu Hospital, Paris, France (project 0611398, registered on 28 February 2007). All participants signed informed consent forms before enrollment in the study.

**Study design.** The study had a double-blind, crossover design, with each participant acting as his or her own control. For each participant, the study involved three series each of three exposures at rest: one series to clean air, one series to 200 ppb (380 μg/m3) NO2, and one series to 600 ppb (1,130 μg/m3) NO2. The order of the three series of exposures was randomized (Figure 1). The design for each series of exposures with the timing of pulmonary function testing, and sputum inductions from day 1 to day 3 is described in Figure 2. For each series, participants were exposed to the same level of NO2 or to clean air.

Sputum was induced twice at baseline (10–30 days before first exposure), with each series of exposures, 6 hr (on day 1), 32 hr (on day 2), and 48 hr (on day 3) after the end of the first exposure. Sputum inductions were separated by 1 hr. There was no exposure on day 3. There was an interval of 2 weeks between each series of exposures. Only the engineer in charge of injection into the chamber knew whether the participant was being exposed to NO2 or clean air.

*Sputum induction and inflammatory marker measurements.* Sputum inductions were performed in an 8.8-m3 exposure chamber installed in the investigation clinical center at the Hospital Bichat in Paris as described previously (Ezratty et al. 2007). The chamber was supplied with fresh, particle-free air at a mean temperature of 25°C and a mean relative humidity of 32%. The air supply passed through HEPA and activated carbon filters. We used NO2 concentrated at 950 ppm compressed in a 20-L gas bottle under 150 bar pressure for the 600-ppb exposures, and a gas bottle of NO2 concentrated at 520 ppm under 150 bar pressure for the 200-ppb exposures (Air Liquide SA, Paris, France). A mass flow meter secured the stability of the injected flow at the expected concentration (200 ppb or 600 ppb).

During exposures, NO2 concentration inside the exposure chamber was continuously monitored (chemiluminescence oxides of nitrogen analyzer, Model AC 32 M; Environnement SA, 78300 Poissy, France). The mean concentration was 581 ppb ± 3.2% for 600-ppb NO2 exposures and 203 ppb ± 1.5% for 200-ppb NO2 exposures. During exposures to clean air, the NO2 concentration was < 10 ppb.

**Nitrogen dioxide/clean air exposure.** The exposures were performed in an 8.8-m3 exposure chamber installed in the investigation clinical center at the Hospital Bichat in Paris as described previously (Ezratty et al. 2007). The chamber was supplied with fresh, particle-free air at a mean temperature of 25°C and a mean relative humidity of 32%. The air supply passed through HEPA and activated carbon filters. We used NO2 concentrated at 950 ppm compressed in a 20-L gas bottle under 150 bar pressure for the 600-ppb exposures, and a gas bottle of NO2 concentrated at 520 ppm under 150 bar pressure for the 200-ppb exposures (Air Liquide SA, Paris, France). A mass flow meter secured the stability of the injected flow at the expected concentration (200 ppb or 600 ppb).

During exposures, NO2 concentration inside the exposure chamber was continuously monitored (chemiluminescence oxides of nitrogen analyzer, Model AC 32 M; Environnement SA, 78300 Poissy, France). The mean concentration was 581 ppb ± 3.2% for 600-ppb NO2 exposures and 203 ppb ± 1.5% for 200-ppb NO2 exposures. During exposures to clean air, the NO2 concentration was < 10 ppb.

**Pulmonary function and methacholine challenge testing.** Flow-volume curves were obtained using a Biomedin spirometer (Biomedin srl, Padova, Italy) according to the European Community Respiratory Health Survey specifications to determine FEV1 and peak expiratory flow (PEF) (Quanjer 1993). Methacholine challenge tests were done twice at baseline with an automatic inhalation-synchronized Mefar MB3 dosimeter jet nebulizer (Mefar spa, Bovezzo, Italy), as described elsewhere (Aubier et al. 1992; Ezratty et al. 2007). Methacholine challenge tests at baseline were conducted 10–30 days before the start of the exposures to avoid any putative interference of the methacholine challenge with the effect of NO2 (Jorres et al. 1995).

**Sputum induction and inflammatory marker measurements.** We performed sputum...
induction with an aerosol of hypertonic saline using the method of Pin et al. (1992). The sputum was analyzed within 1 hr according to Pizzichini et al. (1996), as described elsewhere (Ezratty et al. 2007). Total nonsquamous inflammatory cell counts were expressed as 10⁶ cells/mg of induced sputum. Differential cell counts were performed by counting 400 cells on May Grünwald Giemsa stained slides by two expert observers blinded to the participant’s exposure. Results were expressed both as percentage and as number of inflammatory cells per milligram. Only samples with cell viability > 70% and squamous cell contamination < 20% were considered adequate.

Sputum supernatant concentrations of eosinophil cationic protein (ECP) levels were measured by a commercially available enzyme assay (CAP-FEIA; Pharmacia, St Quentin-en-Yvelines, France), with a lower detection limit of 2 ng/mL.

**Follow-up during the study period.** After 0, 15, and 30 min of exposure to NO₂ or clean air in the chamber, participants were asked questions relating to respiratory symptoms and perception of discomfort. FEV₁ and PEF were monitored twice during exposure at 15-min intervals and hourly for 6 hr after leaving the chamber, with a portable combined spirometer (One Flow Tester; Mediflux, Croissy Beaubourg, France).

During the 10–30 days between baseline measurements and first exposure and during the 2-week interval following each series of exposures, subjective symptoms and medications were recorded every day. Each participant measured FEV₁ and PEF twice daily with a portable combined spirometer.

**Sample size.** The primary end point was the change in the percentage of eosinophils in sputum, expressed as the ratio between the percentage after exposure and the baseline percentage. When the study was designed, literature reports were insufficient to determine the variance of the ratio, which was mandatory to estimate the sample size. Variance was estimated after inclusion of the first eight participants without unblinding. Based on the variance found of 0.10, a sample size of 18 participants was considered sufficient to demonstrate a doubling of the percentage of eosinophils in sputum with a power of 80% and a significance level of 0.05 (see Supplemental Material, Table S1). In addition, a doubling has been reported to be consistent with clinically relevant changes in clinical status of asthmatics (Green et al. 2002).

**Statistical analysis.** The parameters studied in sputum were the percentage of eosinophils, the number of eosinophils per milligram, ECP, the number of neutrophils per milligram, and the number of macrophages per milligram. All parameters were log-transformed to normalize the distributions. We used a generalized linear model (GLM procedure, SAS v9.4; SAS Institute Inc., Cary, NC, USA) for the analyses. We included in the statistical model the effect of the participant, the time, the dose, and the interaction between the time and the dose. The interpretation of the results was based on the type III sum of squares. In case of a significant interaction between day and dose, a global analysis was performed, followed by per-day analyses. In the global analysis, all the data concerning the parameter were summarized by their geometric means (GMs) (in case of sputum inductions, this relates to three sputum inductions over 3 days, one per day), and we tested the relation between NO₂ concentration—used as a quantitative value (0, 200, and 600 ppb)—and the parameter studied. The global analysis provided the trendisons and the confidence limits were exponentiated to obtain the changes relative to the baseline measurements and their confidence intervals (CIs). The per-day analyses were reported only when the trend in the global analysis was significant. p-Values < 0.05 were considered significant.

**Results**

Among the 19 participants, 18 completed the three series of exposures and were included in the analysis. Among those, two did not produce an adequate sample of sputum at all

---

**Figure 1.** Flow diagram of the study period for each participant. Abbreviations: H0, immediately before 1st exposure (day 1); H0’, immediately after 1st exposure (day 1); H6, 6 hr after H0’ (day 1); H32, 32 hr after H0’ (day 2); H48, 48 hr after H0’ (day 3). The dose order was attributed randomly: so, series A, B, and C corresponds to clean air, 200-ppb NO₂, or 600-ppb NO₂ exposure.
time points and were not included in analyses of sputum (Table 1).

Respiratory function—FEV₁ and PEF—measured by spirometry, did not significantly change after NO₂ exposure compared with clean air exposure (Table 2). No major clinical adverse reactions, such as coughing, wheezing, or chest tightness suggesting asthma attacks, were observed during exposures or follow-up. During the 2 weeks after each exposure, subjective symptoms and peak flow measurements were not significantly different regardless of exposure.

The primary analysis tested the exposure level (dose), the time (because the study design included assessment at three time points after exposure, one each day) and the interaction between time and exposure level. The dose was significantly related to the change in the percentage of eosinophils, the time was not. There was a significant interaction between time and exposure level, meaning that the association between dose and effect on eosinophils was different according to the day. As planned in the case of a significant interaction, we performed both a global analysis, averaging the measurements over the 3 days, and per-day analyses.

In the global analysis, the slope of the association between the percentage of eosinophils and NO₂ exposure level was significant (p = 0.04) (Table 3).

Compared with baseline measurements, the percentage of eosinophils in sputum increased by 57% (95% CI: 18, 109%) after 600 ppb NO₂ (p = 0.003) but did not change significantly after clean air or after 200 ppb NO₂.

Similar results were found for the association between the number of eosinophils per milligram of sputum and NO₂ exposure level. In the global analysis, the slope of the association was significant (p = 0.02) (Table 3).

The number of eosinophils per milligram of sputum increased by 120% (95% CI: 60, 202%) after 600 ppb NO₂ (p < 0.001) but not after clean air or after 200 ppb NO₂ (Table 3).

Per-day analysis showed that the slope of the association between the percentage of eosinophils and NO₂ exposure level was not significant at day 1 (p = 0.81), but was significant at day 2 (p = 0.01) and day 3 (p = 0.03). A similar pattern was found for the slope of the association between the number of eosinophils per milligram of sputum and the level of exposure to NO₂, which was not significant at day 1 (p = 0.10), close to significance at day 2 (p = 0.06), and significant at day 3 (p = 0.03) (Table 3; see also Supplemental Material, Figure S1).

Compared with baseline measurements, there was no significant change of the percentage of eosinophils in sputum regardless of the level of exposure to NO₂ at day 1. At day 2, the percentage and the number of eosinophils increased significantly after 600 ppb NO₂.

Figure 2. Study design for each of the three series of exposures separated by 2 weeks. Abbreviations: H₀, immediately before 1st exposure (day 1); H₀', immediately after 1st exposure (day 1); H₆, 6 hr after H₀' (day 1); H₃₂, 32 hr after H₀' (day 2); H₄₈, 48 hr after H₀' (day 3). Participants were exposed at rest in a double-blinded, randomized, crossover design to clean air, 200-ppb NO₂, or 600 ppb NO₂ once for 30 min on day 1, and twice for 30 min on day 2. There was no exposure on day 3. Time of day is expressed in military form.
Ezratty et al.

Eosinophils increased significantly at 600 ppb, but not at 200 ppb NO2. At day 3, the number of eosinophils increased significantly at 200 ppb and at 600 ppb NO2, and the increase of the percentage of eosinophils was close to significance at 600 ppb NO2, but not significant at 200 ppb (Table 3; see also Supplemental Material, Figure S1).

Absolute values not baseline adjusted [GMs (95% CIs)] of the percentages of eosinophils are reported in Supplemental Material, Table S2. Individual plots of the percentage of eosinophils are displayed in Supplemental Material, Figure S2. In order to see if results were driven by a participant in particular, we did a sensitivity analysis: a series of analyses with one different participant removed for each analysis. The trend test that measures the relationship between the dose of NO2 and the increase of the percentage of eosinophils in sputum from baseline was significant (p < 0.05) in 10 of the tests, and was close to significance (p < 0.10) for the other participants. Moreover, the increase of the percentage of eosinophils in sputum compared with baseline measurements was always significant at 600 ppb, regardless of which participant was removed from the analysis (see Supplemental Material, Table S3).

There was a significant correlation between the number of eosinophils per milligram of sputum and ECP in nanograms per milliliter (p < 0.001) (see Supplemental Material, Figure S3).

Compared with baseline measurements, ECP in sputum increased significantly after exposure to 600 ppb NO2 (43%; 95% CI: 17; 75%; p = 0.001) but not after exposure to clean air or 200 ppb NO2. However, the slope of the association between ECP and the level of exposure was not significant (Table 3).

Exposure to NO2 did not affect the other cell types (macrophages, neutrophils) measured in sputum (Table 3).

There was no correlation between methacholine challenge tests and eosinophil responses (data not shown).

Discussion

Our findings indicate that repeated brief exposures to NO2 without allergen exposure increase eosinophilic airway inflammation in participants with intermittent asthma without inducing any changes in lung function. Because only mild asthmatics were tested, the results cannot be extrapolated to healthy individuals.

Although we cannot exclude that repeated challenges with hypertonic saline could have potentialized the effect of NO2, the repetition of sputum inductions is not the cause of the effect because the effect is expected to be the same for each of the three series of exposures (Pavord 1998). Eosinophils in sputum increased according to NO2 exposure level, and this significant trend supports a dose-related relationship. The effect on eosinophils and on ECP in sputum was significant at 600 ppb NO2. We found a strong correlation between ECP and eosinophils, suggesting that eosinophils were activated.

In participants with asthma, several studies have found that NO2 exposure increased eosinophilic inflammation in response to inhaled allergens, in the distal lower airways assessed by bronchial wash and bronchoalveolar lavage (BAL) (Barck et al. 2002), and in sputum (Barck et al. 2005). The previous studies that have investigated effects of NO2 without allergen challenge in participants with asthma did not find changes in inflammatory cell distributions in BAL (Jorres et al. 1995) and in sputum (Solomon et al. 2004; Vagaggini et al. 1996). However, these studies involved small numbers of participants, and no repetition of exposure, and, in the study by Jorres et al. (1995), the evaluation of inflammation could have been performed too soon after exposure.

In the present study, participants with asthma were exposed to two realistic NO2 concentrations: 200 ppb and 600 ppb of NO2, which are close to NO2 peaks likely to be found indoors during the use of combustion appliances for cooking and heating (Basi and Samet 1999; Dennekamp et al. 2001; Kozias et al. 2005; Pilotto et al. 1997) and outdoors for short periods in streets with heavy traffic and in road tunnels (Larsson et al. 2010). Exposures lasted 30 min, close to the average time spent cooking dinner in France (38 min during the week and 46 min the weekend in a 2003 survey) (Hebel 2012). Furthermore, exposure to intermittent peaks of NO2 may have greater effects than long-term, low-level exposure (Gardner et al. 1979).

Exposures in the present study were repeated over 2 days to mimic how exposures take place in real life and in order to assess a possible cumulative effect. At day 1, after one exposure, there was no significant change in eosinophilic airway inflammation—contrary to day 2 and day 3, after three exposures. These findings suggest that inflammatory response to NO2 exposure may be delayed or that a single exposure may be insufficient to enhance eosinophilic airway inflammation, suggesting a cumulative effect of NO2. These results are consistent with those of Barck et al. (2005) who found that two to three brief exposures at 260 ppb NO2 were needed to promote an increase in the airway inflammatory response to inhaled allergens. In addition to the study by Barck et al. (2005), our study shows that NO2, without an exposure to a high concentration of allergens, as with an allergen challenge, is sufficient to enhance inflammation in the airways. This finding could be of significance because exposure to peaks of NO2 is common, particularly indoors, whereas exposure to both high concentrations of NO2 and the specific stimulus for a susceptible individual is less likely (Hesterberg et al. 2009).

Many cities in Europe show an increase in concentrations of NO2 measured close to traffic due to the increasing number of vehicles, in particular diesel vehicles. Exhaust emissions from diesel vehicles are lower for carbon monoxide, non-methanic volatile organic compounds, and particulate matter

Table 2. GMS (95% CIs) of values relative to baseline of FEV1 and PEF evaluated in the 18 participants who completed the study.

<table>
<thead>
<tr>
<th>Variable</th>
<th>0 ppb NO2 (clean air)</th>
<th>200 ppb NO2</th>
<th>600 ppb NO2</th>
<th>pValue</th>
</tr>
</thead>
<tbody>
<tr>
<td>FEV1/baseline</td>
<td>1.02 (1.00, 1.05)</td>
<td>1.00 (0.97, 1.03)</td>
<td>1.00 (0.98, 1.03)</td>
<td>0.41</td>
</tr>
<tr>
<td>PEF/baseline</td>
<td>1.05 (0.99, 1.11)</td>
<td>1.04 (0.98, 1.10)</td>
<td>1.01 (0.96, 1.07)</td>
<td>0.36</td>
</tr>
</tbody>
</table>

Baseline values were measured immediately before first exposure (H0 on day 1) for each series of exposure. Each value corresponds to the GM change from baseline of the six values (H0, immediately after first exposure (day 1); H1, 6 hr after H0 (day 1); H2, 24 hr after H0 (day 2); H48, 48 hr after H0 (day 3)) obtained by spirometry with flow-volume curves. The effects of exposure, regardless of the dose, on FEV1 and PEF were not significant.

Table 3. Changes relative to baseline measurements (performed 10–30 days before the first exposure) for parameters measured in sputum [GM (95% CI), n = 16].

<table>
<thead>
<tr>
<th>Variable</th>
<th>0 ppb NO2 (clean air)</th>
<th>200 ppb NO2</th>
<th>600 ppb NO2</th>
<th>pTrend</th>
</tr>
</thead>
<tbody>
<tr>
<td>Percentage of eosinophils</td>
<td>–12 (–34, 16)</td>
<td>–5 (–28, 26)</td>
<td>57 (18, 109)**</td>
<td>0.04</td>
</tr>
<tr>
<td>Day 1</td>
<td>–34 (–59, 8)</td>
<td>12 (–31, 79)</td>
<td>0.81</td>
<td></td>
</tr>
<tr>
<td>Day 2</td>
<td>–3 (–36, 46)</td>
<td>102 (22, 211)**</td>
<td>0.01</td>
<td></td>
</tr>
<tr>
<td>Day 3</td>
<td>–36 (–26, 149)</td>
<td>79 (–3, 230)</td>
<td>0.03</td>
<td></td>
</tr>
<tr>
<td>No. of eosinophils/mg</td>
<td>–31 (–3, 29)</td>
<td>23 (–10, 88)</td>
<td>120 (60, 202)**</td>
<td>0.02</td>
</tr>
<tr>
<td>Day 1</td>
<td>–5 (–44, 60)</td>
<td>–24 (–55, 29)</td>
<td>64 (–3, 177)</td>
<td>0.10</td>
</tr>
<tr>
<td>Day 2</td>
<td>9 (31, 95)</td>
<td>23 (–31, 119)</td>
<td>142 (32, 344)**</td>
<td>0.06</td>
</tr>
<tr>
<td>Day 3</td>
<td>–18 (–57, 56)</td>
<td>99 (5, 278)*</td>
<td>163 (38, 398)**</td>
<td>0.03</td>
</tr>
<tr>
<td>ECP</td>
<td>21 (–1, 47)</td>
<td>0 (–18, 22)</td>
<td>43 (17, 75)**</td>
<td>0.23</td>
</tr>
<tr>
<td>No. of neutrophils/mg</td>
<td>–5 (–31, 22)</td>
<td>10 (–18, 49)</td>
<td>0.97</td>
<td></td>
</tr>
<tr>
<td>No. of macrophages/mg</td>
<td>–18 (–33, 0)</td>
<td>–6 (–24, 15)</td>
<td>0.46</td>
<td></td>
</tr>
</tbody>
</table>

GM percentages represent all changes of the parameter for the 3 days (one sputum induction per day).

*p < 0.05; **p < 0.01; and *p < 0.001, compared with baseline.
but may be higher for NO₂ (Guerreiro et al. 2012). Although epidemiological studies on NO₂ have several limitations in particular because of the potential for exposure misclassification and co-pollutant effects, our results provide important evidence suggesting that NO₂ alone has a direct effect on airway inflammation in asthmatics.

**Conclusions**

To our knowledge, this is the first study to demonstrate that repeated peaks of NO₂ at realistic concentrations without allergen exposure increase eosinophilic inflammation in the airways of asthmatics, supporting a dose–response relationship. Although it is difficult to evaluate the clinical implications of these findings in the present study, an increased eosinophilic inflammation may lead to exacerbation or loss of control of asthma (Green et al. 2002; Jacobsen et al. 2007). Therefore, we cannot rule out the effects of repeated exposures to NO₂ over a longer period of time or effects in subpopulations.

**References**


Avol EL, Linn WS, Peng RC, Valencia G, Little D, Hackney JD. 2002; Jacobsen et al. 2007). Therefore, eosinophilic inflammation may lead to exacerbation of asthma following exposure to nitrogen dioxide (NO₂) exposures for a longer period of time. 


